2696 — Shanghai Henlius Biotech Cashflow Statement
0.000.00%
- HK$20.57bn
- HK$23.63bn
- CNY5.72bn
- 35
- 19
- 95
- 49
Annual cashflow statement for Shanghai Henlius Biotech, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -994 | -957 | -694 | 570 | 846 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 133 | 336 | 299 | 161 | 106 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 116 | 511 | 1,099 | -41.8 | -84.9 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -610 | 90.4 | 982 | 1,048 | 1,242 |
Capital Expenditures | -557 | -1,131 | -1,365 | -1,011 | -837 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -955 | -550 | 6.56 | 7.01 | -72.8 |
Acquisition of Business | |||||
Sale of Fixed Assets | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Change in Net Intangibles | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -1,512 | -1,681 | -1,359 | -1,004 | -910 |
Financing Cash Flow Items | -54.7 | -83.4 | -115 | -130 | -133 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 996 | 648 | 858 | 144 | -643 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -1,187 | -959 | 518 | 194 | -296 |